標(biāo)題: Titlebook: Biological Mechanisms of Minimal Residual Disease and Systemic Cancer; Julio A.‘Aguirre-Ghiso Book 2018 Springer Nature Switzerland AG 201 [打印本頁] 作者: finesse 時間: 2025-3-21 18:09
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer影響因子(影響力)
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer影響因子(影響力)學(xué)科排名
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer網(wǎng)絡(luò)公開度
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer被引頻次
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer被引頻次學(xué)科排名
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer年度引用
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer年度引用學(xué)科排名
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer讀者反饋
書目名稱Biological Mechanisms of Minimal Residual Disease and Systemic Cancer讀者反饋學(xué)科排名
作者: malapropism 時間: 2025-3-21 20:43
Minimal Residual Disease in Prostate Cancer,ence, but has not yet been routinely used in clinical care. Investigators have detected MRD by identification of prostate cancer cells in the bone marrow; termed disseminated tumor cells (DTCs) and blood; termed circulating tumor cells (CTCs). Various techniques including PSA-RT PCR, PSA immunocytoc作者: Decline 時間: 2025-3-22 03:41 作者: 賠償 時間: 2025-3-22 05:14
Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Ponitoring for minimal residual disease (MRD) during a disease-free follow-up period would greatly improve patient outcomes through earlier detection of relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clin作者: Cytokines 時間: 2025-3-22 11:00 作者: AVOW 時間: 2025-3-22 13:28 作者: Heresy 時間: 2025-3-22 17:39 作者: Tinea-Capitis 時間: 2025-3-22 23:28
Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Hel response exceed 90% and complete response (CR) more than 50% in some studies. Unfortunately, despite higher rates of CR, relapse rates remain high suggesting that persistent disease may not be measured by current techniques. Traditionally, response rates were defined by urine and serum protein ele作者: heart-murmur 時間: 2025-3-23 03:45 作者: 分開 時間: 2025-3-23 08:53 作者: Offstage 時間: 2025-3-23 12:29
https://doi.org/10.1007/978-3-658-18524-4uantitatively assess residual disease and accurately prognosticate PFS and OS in myeloma. In this chapter, we will discuss the current techniques for MRD detection as well as describe techniques that are emerging for improved characterization of drug resistant residual populations that could be adap作者: Capture 時間: 2025-3-23 17:00
0065-2598 . ??..?..This book is edited and prefaced by Dr. Julio Aguirre-Ghiso, an expert in dormancy and recurrence. The chapters are written by world-recognized experts Drs. Ravi Bahtia, Samir Parekh, Russel Taichman, 978-3-319-97746-1Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: Irrigate 時間: 2025-3-23 18:34 作者: MUT 時間: 2025-3-23 23:32
Biological Mechanisms of Minimal Residual Disease and Systemic Cancer作者: 天空 時間: 2025-3-24 04:28
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironmelated to tyrosine kinase independent mechanisms which include intrinsic properties of LSCs determined by epigenetic alterations, altered transcriptional regulatory networks or mitochondrial/metabolic changes. In addition to cell intrinsic changes, signals from the bone marrow microenvironment (BMM) 作者: Armory 時間: 2025-3-24 06:38
Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heuantitatively assess residual disease and accurately prognosticate PFS and OS in myeloma. In this chapter, we will discuss the current techniques for MRD detection as well as describe techniques that are emerging for improved characterization of drug resistant residual populations that could be adap作者: A精確的 時間: 2025-3-24 12:11
Auf das Nerven system wirken de Stoffe,ion, anti-angiogenic agents were expected to suppress the growth of any type of primary or metastatic tumor, independent of their subtype or genetic landscape. However, more that 20?years after the first anti-angiogenic preclinical trial, the astonishing inhibition of metastatic outgrowth originally作者: 無意 時間: 2025-3-24 15:49 作者: 親密 時間: 2025-3-24 19:43 作者: Nebulous 時間: 2025-3-25 01:32 作者: 艦旗 時間: 2025-3-25 03:36 作者: 心神不寧 時間: 2025-3-25 09:28 作者: OREX 時間: 2025-3-25 12:52 作者: Friction 時間: 2025-3-25 16:10
https://doi.org/10.1007/978-3-658-18524-4l response exceed 90% and complete response (CR) more than 50% in some studies. Unfortunately, despite higher rates of CR, relapse rates remain high suggesting that persistent disease may not be measured by current techniques. Traditionally, response rates were defined by urine and serum protein ele作者: Indurate 時間: 2025-3-25 22:51
Biological Mechanisms of Minimal Residual Disease and Systemic Cancer978-3-319-97746-1Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: APRON 時間: 2025-3-26 00:22 作者: 救護(hù)車 時間: 2025-3-26 07:46 作者: 返老還童 時間: 2025-3-26 10:57 作者: Leisureliness 時間: 2025-3-26 14:54
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/b/image/187399.jpg作者: acolyte 時間: 2025-3-26 19:31
Book 2018ematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into tech作者: Hemoptysis 時間: 2025-3-27 00:44 作者: JOG 時間: 2025-3-27 02:00
Mittel zur Behandlung von Virusinfektionen,f relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.作者: 最有利 時間: 2025-3-27 08:01
Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Pf relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.作者: 止痛藥 時間: 2025-3-27 09:47 作者: Endoscope 時間: 2025-3-27 16:47
Auf die Niere und Harnwege wirkende Stoffe,ent approaches to assess residual disease including the 2018 European Leukemia Network (ELN) working group recommendations for MRD standardization in AML. In addition, a summary of MRD studies associated to prognosis will be described.作者: Ptsd429 時間: 2025-3-27 19:21
,Fachwerktr?ger und Stabkr?fte,scuss existing . models of minimal residual disease based on different cellular labelling strategies and engraftment of ALL cells in immunodeficient mouse strains. We finally draw some conclusions on potential strategies targeting residual ALL cells, with a focus on cellular and antibody-based immunotherapy.作者: 鳴叫 時間: 2025-3-28 00:23
Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer,rare disseminated tumor cells (DTC). The aim of this chapter is to comprehensively inform the reader about the detection, the mode of spread, the clinical relevance, and the biology of DTCs in HNSCC and EC. A better understanding of DTCs will be key to suppress progression of the upper digestive tract cancers more effectively.作者: 讓你明白 時間: 2025-3-28 06:04
Minimal Residual Disease in Acute Myeloid Leukemia,ent approaches to assess residual disease including the 2018 European Leukemia Network (ELN) working group recommendations for MRD standardization in AML. In addition, a summary of MRD studies associated to prognosis will be described.作者: cumulative 時間: 2025-3-28 08:43
Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblasscuss existing . models of minimal residual disease based on different cellular labelling strategies and engraftment of ALL cells in immunodeficient mouse strains. We finally draw some conclusions on potential strategies targeting residual ALL cells, with a focus on cellular and antibody-based immunotherapy.作者: 不理會 時間: 2025-3-28 14:16 作者: Suppository 時間: 2025-3-28 15:09
